{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-045568","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.976596+00:00","generated_at":"2026-05-25T15:05:24.086454+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nuvation Bio secures up to $250M in debt and royalty financing for taletrectinib","bullets":["$100M loan with Sagard; initial $50M tranche upon FDA approval of taletrectinib by Sep 30, 2025; second $50M upon first US commercial sale by Jun 30, 2026","Loan matures Sep 30, 2030, interest SOFR (4% floor) + 6% quarterly; prepayment premiums; $25M minimum cash covenant","$150M revenue interest financing; tiered royalties: 5.5% on US net sales up to $600M, 3.0% on $600M-$1B, none above $1B","Royalty obligation ends at 1.6x-2.0x investment amount; true-up if not repaid by Feb 1, 2043","Company can buy out royalty at 140%-200% of investment amount less payments made; investor can put upon certain events"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-045568","json":"https://secwatch.observer/filing/0001193125-25-045568.json","markdown":"https://secwatch.observer/filing/0001193125-25-045568.md","text":"https://secwatch.observer/filing/0001193125-25-045568.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525045568/0001193125-25-045568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525045568/d918004d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T15:05:24.086454+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}